Phenyramidol

As a representative variety of central muscle relaxants, phenyramidol inhibits the polysynaptic reflex at the spinal cord level and blocks the transmission of pain signals to the central nervous system, while exerting mild analgesic and anti-inflammatory effects. Clinically, it is mainly used to relieve acute spasmodic pain caused by musculoskeletal diseases, including lumbar muscle strain, scapulohumeral periarthritis, sprain and contusion, postoperative muscle rigidity and other conditions. It is suitable for adult patients with acute and chronic pain accompanied by muscle tension, and can be administered alone or in combination with non-steroidal anti-inflammatory drugs to help patients quickly improve the problem of limited activity and improve the quality of life during the recovery period of the disease.

At present, the global market size of phenyramidol is approximately USD 320 million, with a compound annual growth rate of 4.1% in the past three years. The growth momentum mainly comes from the rising prevalence of sports injuries and the increasing demand for diagnosis and treatment of muscle degenerative diseases in the elderly. The domestic market is still in the cultivation stage, with a small number of generic drug application enterprises. Currently, fewer than 5 preparation products have been approved, no relevant varieties have been included in the national centralized volume-based procurement scope, the supply gap of API is relatively obvious, and the degree of market competition is relatively mild.

The original research enterprise of phenyramidol is Bayer AG of Germany, with the original research brand name Preludin. The core compound patent expired globally in 1982, and the main marketed dosage form at present is 100 mg oral tablet. The original research tablet has been included in the FDA Orange Book Reference Listed Drug Catalog, but has not yet been included in the *Catalog of Reference Preparations for Chemical Drugs* of China. At present, there is no publicly announced A-state API registration number of phenyramidol in China, nor are there any imported or domestic phenyramidol preparations approved for marketing. (Data as of July 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of phenyramidol impurity reference standards, most of which are in regular stock. Spot orders paid before 16:00 can be shipped on the same day. All reference standards comply with the requirements of multiple national regulations including the Chinese Pharmacopoeia and FDA. The complete structure confirmation and purity testing reports can directly support the registration application and quality research of APIs, and fully meet the impurity reference standard needs of the R&D and production ends.